Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase.
Cancer Med
; 2022 Jul 15.
Article
in English
| MEDLINE | ID: covidwho-2245562
ABSTRACT
OBJECTIVE:
Allergic reactions to pegaspargase during ALL therapy are typically due to antibodies against polyethylene glycol (PEG), which is also used as a stabilizing agent in mRNA-based SARS-CoV-2 vaccines. To evaluate the safety of these vaccines in patients with anti-pegaspargase antibodies.METHODS:
We retrospectively reviewed the records of patients treated for ALL who had received SARS-CoV-2 vaccinations. All patients had antibodies against pegaspargase assayed during ALL therapy prospectively and in response to clinical allergies. Symptoms of intolerance to vaccination were gathered retrospectively from chart abstraction.RESULTS:
SARS-CoV-2 vaccination was well tolerated in all 78 patients with prior exposure to pegaspargase as part of their leukemia therapy. No reactions were observed in the 54 patients without a history of anti-pegaspargase antibodies or in 19 patients with antibodies who received mRNA vaccination. 1 patient who received the polysorbate containing Janssen vaccine experienced mild symptoms after vaccination not meeting the criteria of clinical allergy which spontaneously resolved within 25 minutes.CONCLUSION:
SARS-CoV-2 vaccination is safe in this population.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Cam4.5011
Similar
MEDLINE
...
LILACS
LIS